Memphasys Limited (ASX: MEM) is an Australian-based reproductive biotechnology company commercialising the Felix™ System – a patented sperm separation technology that isolates the most viable sperm cells for human assisted reproductive technology (ART).

 The Felix™ System is CE marked, included in the Australian Register of Therapeutic Goods (ARTG), and registered with the UK Medicines and Healthcare products Regulatory Agency (MHRA). It is now deployed in ART clinics across Europe, Australia, the Middle East, Japan and New Zealand – generating record recurring revenue.